Want to see IMVT full AI Analyst Report?
Total Valuation
Immunovant has a market cap or net worth of $8.64B. The enterprise value is $7.12K.
Market Cap$8.64B
Enterprise Value$7.12K
Share Statistics
Immunovant has 206,552,690 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding206,552,690
Owned by Insiders56.19%
Owned by Institutions4.30%
Financial Efficiency
Immunovant’s return on equity (ROE) is -0.59 and return on invested capital (ROIC) is -62.46%.
Return on Equity (ROE)-0.59
Return on Assets (ROA)-0.53
Return on Invested Capital (ROIC)-62.46%
Return on Capital Employed (ROCE)-0.62
Revenue Per Employee0.00
Profits Per Employee-1.61M
Employee Count315
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Immunovant is ―. Immunovant’s PEG ratio is -6.12.
PE Ratio―
PS Ratio0.00
PB Ratio5.31
Price to Fair Value5.31
Price to FCF-11.12
Price to Operating Cash Flow-20.75
PEG Ratio-6.12
Income Statement
In the last 12 months, Immunovant had revenue of 0.00 and earned -505.61M in profits. Earnings per share was -2.77.
Revenue0.00
Gross Profit-409.00K
Operating Income-532.90M
Pretax Income-505.39M
Net Income-505.61M
EBITDA-504.98M
Earnings Per Share (EPS)-2.77
Cash Flow
In the last 12 months, operating cash flow was -414.30M and capital expenditures -8.00K, giving a free cash flow of -414.31M billion.
Operating Cash Flow-414.30M
Free Cash Flow-414.31M
Free Cash Flow per Share-2.01
Dividends & Yields
Immunovant pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.01
52-Week Price Change174.05%
50-Day Moving Average37.98
200-Day Moving Average29.14
Relative Strength Index (RSI)64.04
Average Volume (3m)1.35M
Important Dates
Immunovant upcoming earnings date is Oct 30, 2026, Before Open (Confirmed).
Last Earnings DateAug 6, 2026
Next Earnings DateOct 30, 2026
Ex-Dividend Date―
Financial Position
Immunovant as a current ratio of 9.09, with Debt / Equity ratio of 0.00%
Current Ratio9.09
Quick Ratio9.09
Debt to Market Cap0.00
Net Debt to EBITDA1.79
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Immunovant has paid 215.00K in taxes.
Income Tax215.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Immunovant EV to EBITDA ratio is -7.19, with an EV/FCF ratio of -8.91.
EV to Sales0.00
EV to EBITDA-7.19
EV to Free Cash Flow-8.91
EV to Operating Cash Flow-8.91
Balance Sheet
Immunovant has $797.80M in cash and marketable securities with $0.00 in debt, giving a net cash position of $797.80M billion.
Cash & Marketable Securities$797.80M
Total Debt$0.00
Net Cash$797.80M
Net Cash Per Share$3.86
Tangible Book Value Per Share$4.67
Margins
Gross margin is 97.10%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin97.10%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Immunovant is $51.27, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$51.27
Price Target Upside30.10% Upside
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast―
EPS Growth Forecast1.28%